Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation
2 other identifiers
observational
66
1 country
1
Brief Summary
To understand the changes in health-related quality of life of patients and caregivers after allogeneic hematopoietic cell transplantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 22, 2025
CompletedFirst Posted
Study publicly available on registry
August 26, 2025
CompletedStudy Start
First participant enrolled
September 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2028
ExpectedMarch 10, 2026
March 1, 2026
7 months
August 22, 2025
March 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Quality of Life Questionnaire
You will answer questionnaires with a member of the research team. The questionnaires will take about 35 minutes complete. You will be asked questions about your sleep, anxiety and depressive symptoms, fatigue, distress, and your quality of life.
Through study completion; an average of 1 year
Interventions
You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate. Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet.
Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.
Eligibility Criteria
MD Anderson Cancer Center
You may not qualify if:
- Participant or caregiver unable to provide consent, such as cognitively impaired individuals
- Participant or caregiver with a diagnosis of sleep apnea.
- Primary caregiver is a paid professional, such as a live-in Registered Nurse.
- Participant has multiple caregivers and is unable to identify one primary caregiver.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eileen D Hacker, MD
M.D. Anderson Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 22, 2025
First Posted
August 26, 2025
Study Start
September 2, 2025
Primary Completion
April 1, 2026
Study Completion (Estimated)
April 1, 2028
Last Updated
March 10, 2026
Record last verified: 2026-03